Spots Global Cancer Trial Database for Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
Official Title: A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer
Study ID: NCT00005027
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
Detailed Description: OBJECTIVES: * Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue. * Assess the quantitative and qualitative toxicities associated with this drug in this patient population. OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Contact Details
Name: Ulka N. Vaishampayan, MD
Affiliation: Barbara Ann Karmanos Cancer Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
